425: Atlantic Coastal Acquisition Corp. II Announces Proposed Business Combination with Abpro Corporation

Atlantic Coastal Acquisition Corp. II (ACAB) has filed an amendment to its Registration Statement on Form S-4 regarding its proposed business combination with Abpro Corporation, including a revised investor presentation.

Summary

• Atlantic Coastal Acquisition Corp. II (ACAB) is pursuing a business combination with Abpro Corporation at a purchase price of approximately $500 million.
• The transaction is expected to be funded through a combination of PIPE financing ($6.4 million) and ACAB cash in trust ($6.2 million).
• Abpro shareholders will rollover 100% of their equity, representing approximately 78% of the pro forma equity value.
• Net proceeds are intended to fund Abpro's operations, including R&D and clinical development of its lead programs.
• The transaction is targeted to close in Q4 2024, pending customary approvals.
• Abpro's pipeline includes ABP-102 (HER2/CD3) for breast and gastric cancer, ABP-201 (VEGF/ANG2) for wet AMD and DME, ABP-110 (GPC3/CD3) for liver cancer, and ABP-150 (Claudin18.2/CD3) for gastric cancer.
• Abpro has a strategic partnership with Celltrion for the development and commercialization of ABP-102, potentially worth up to $1.75 billion to Abpro.
• ABP-201 is being co-developed via a territorial partnership with Abpro Bio, with Abpro retaining U.S. and European Union commercial rights.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the proposed business combination and Abpro's pipeline, but also acknowledges the inherent risks and uncertainties associated with the transaction and drug development.

Positives

• The business combination provides Abpro with significant funding to advance its pipeline.
• The partnership with Celltrion for ABP-102 provides financial support and expertise.
• Abpro's DiversImmune platform has been validated by global pharma and research institutions.
• Abpro's pipeline targets large addressable markets, including breast cancer, gastric cancer, liver cancer, wet AMD, and DME.
• Preclinical data for ABP-201 shows positive results in in vivo models.

Negatives

• The transaction is subject to customary closing conditions and approvals, which may not be met.
• The amount of cash available from the trust account is subject to redemption requests by ACAB's stockholders.
• The projected financial information is subject to uncertainty and may not be indicative of future results.
• Abpro's success depends on the regulatory approval and commercialization of its products, which is not guaranteed.

Risks

• The business combination may not be completed in a timely manner or at all.
• Failure to satisfy the conditions to the consummation of the Proposed Business Combination.
• The effect of the announcement or pendency of the Proposed Business Combination on Abpros business relationships, performance and business generally.
• Risks related to Abpros ability to achieve and maintain profitability and generate cash.
• The potential inability of Abpro to manage growth effectively.
• Abpros dependence on senior management and other key employees.
• The inability to successfully bring Abpros products to market (including obtaining regulatory approval).
• The early termination of any of Abpros existing agreements to develop its products.

Future Outlook

The document outlines Abpro's anticipated clinical development timeline, including plans to file IND applications and initiate clinical trials for its lead programs. The company anticipates several upcoming GLP-Tox Study and IND-Enabling Study Completions.

Industry Context

The announcement reflects the ongoing trend of SPAC mergers in the biotech industry, providing companies like Abpro with an alternative route to public markets and access to capital. Abpro is positioning itself in the competitive landscape of antibody therapies, targeting diseases with significant unmet needs.

Comparison to Industry Standards

• Abpro's ABP-201, targeting VEGF and ANG-2 for wet AMD and DME, is positioned to compete with existing treatments like Eylea and Lucentis, as well as newer bispecific antibodies like Vabysmo.
• The company claims ABP-201 has a longer half-life in the eye than Eylea, which contributes to pharmacological durability.
• Abpro's TetraBi format is presented as having advantages over firstand second-generation T-cell engagers, including stronger binding to tumor cells and a reduced risk of immunogenicity.

Stakeholder Impact

• Shareholders of ACAB will have the opportunity to vote on the proposed business combination.
• Abpro's employees may be affected by the integration of the two companies.
• The business combination could lead to the development and commercialization of new therapies for patients facing severe and life-threatening diseases.

Next Steps

• ACAB will mail a definitive proxy statement/prospectus to its stockholders.
• ACAB and Abpro stockholders need to approve the Proposed Transactions.
• The parties need to satisfy customary closing conditions and obtain required regulatory approvals.
• Abpro plans to file an IND application and initiate a Phase 1 trial for ABP-201 in Q1 2026.

Key Dates